Reata Pharmaceuticals Overview
Latest P/E ratio for Reata Pharmaceuticals: -20.07 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-20.07
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Reata Pharmaceuticals (RETA) currently reports a P/E ratio of -20.07. That is below the Healthcare sector average of 27.42. Use the charts on this page to explore Reata Pharmaceuticals's P/E ratio history and peer comparisons.
Reata Pharmaceuticals's P/E ratio of -20.07 is lower than the Healthcare sector average of 27.42. That is roughly 173.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Reata Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At -20.07, RETA can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -20.07, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 27.42. From there, open related valuation or income-statement pages for Reata Pharmaceuticals, and consider following RETA for alerts when major investors trade the stock.
Reata Pharmaceuticals is classified in the Healthcare sector. On P/E ratio, it currently shows -20.07 versus a sector average near 27.42. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RETA with unrelated industries.
